Elicio Therapeutics

ELTX

Biotechnology · Healthcare

Price

$3.04

-0.04 (-1.14%)

Market Cap

$58.0M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+378.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.2M (2021) → 15.3M (2025)

Winston Score History

The full picture

Elicio Therapeutics is a small biotech company that develops experimental cancer vaccines. Its main technology is called Amphiphile, or "AMP," which is designed to train the immune system to recognize and attack cancer cells. The company is focused on treating cancers like pancreatic cancer and other solid tumors, and its customers would eventually be patients and healthcare providers if its drugs reach approval.

Elicio makes no product revenue yet — it is a clinical-stage company, meaning its drugs are still being tested in human trials. It is based in Boston, Massachusetts, and operates almost entirely in the United States. The company funds itself through stock offerings and grants rather than product sales, which is typical for early-stage biotechs. Its main risk is that clinical trials are expensive and often fail, and with a market cap of only around $100 million, Elicio has limited financial runway to advance its pipeline without raising additional capital.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+34.8% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$25M/ year

↓ Declining (-26% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

53.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~9 months

$23M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Elicio Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-217.0%

Weak — -217.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.20

Elevated debt (1.20)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial